GLPwatch
[New drugs in type 2 diabetes mellitus therapy].
Vnitr Lek · 2013
Last updated 2026-05-28New diabetes drugs like lixisenatide, weekly exenatide, dapagliflozin, and insulin degludec have been approved, while once-weekly gliptins and other treatments are still being developed. These drugs aim to improve safety and effectiveness in managing type 2 diabetes.
AI summary of the abstract below.
| Journal | Vnitr Lek, 2013 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
The objective in developing a new type 2 diabetes therapy is to achieve greater safety and better efficacy. Newly registered drugs include lixisenatide, QW exenatide, dapagliflozin and insulin degludec. Once weekly gliptins and other substances are under development.
Verbatim abstract via PubMed 24007229 ↗